·糖尿病临床研究·

　　【摘要】 目的 观察用磷酸西格列汀治疗新诊断T2DM的有效性和安全性。 方法 139例新确诊T2DM患者，按照HbA1c水平分为A、B、C三组，采用二肽基肽酶4(DPP-Ⅳ)抑制剂磷酸西格列汀(捷诺维)100 mg，1次/d口服治疗，持续治疗52周。 结果 治疗52周后，3组HbA1c分别由12.0%、8.4%、6.8%降至7.1%、6.9%、6.5%。FBG、2 hBG、胰岛素释放水平与治疗前比较差异均有统计学意义(P<0.05)。肝肾功能、血脂、UA1b、BMI与治疗前比较差异无统计学意义(P>0.05)。有3例发生低血糖事件，未发生其他不良反应。 结论 用磷酸西格列汀(捷诺维)治疗新诊断T2DM患者，可安全有效的降低HbA1c、7个时点(三餐前后、睡前)血糖。

　　【关键词】 糖尿病，2型;磷酸西格列汀(捷诺维);糖化血红蛋白

Clinical observation of Sitagliptin Phosphat treatment in newly diagnosed type 2 diabetes  RU Yan-zhi,MA Hong, LAN Li-zhen. Deparment of Endocrinology, The First Clinical Medical College, Shanxi Medical University, Taiyuan 030001,China

　　【Abstract】 Objective To observe the efficiency and safety of Sitagliptin Phosphate treatment in newly diagnosed type 2 diabetes. Methods Among patients with newly diagnosed type 2 diabetes, 139 of them were divided into A, B and C groups. In accordance with the level of glycated hemoglobin. 52-week oral treatment was used once a day, with 100 mg of dipeptidyl peptidase 4 (DDP Ⅳ) inhibitor—sitagliptin phosphate (januvia). Results After 52 weeks, HbA1c were decreased from 12.0%, 8.4%, 6.8% to 7.1%, 6.9%, 6.5% in A、B、C groups respectively. FBG, 2 hBG and insulin release level had statistical significance differences compared with those before treatment (P<0.05). The levels of liver and kidney function, blood lipid, urinary albumin, body mass index had no significant difference among three groups (P>0.05) compared with those before treatment. Three cases had hypoglycemia reaction symptoms, and adverse reaction was not found. Conclusion Using Sitagliptin Phosphate (januvia) to treat newly dignosed type 2 diabetes can reduce glycosylated hemoglobin and 7 time blood glucose (before and after meals, at bedtime) safely, effectively, conveniently and reliably.

　　【Key words】 Diabetese mellitus, type 2; Glycosylated hemoglobin;Sitagliptin phosphate (januvia);